Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authorid0000-0002-3836-2125en_US
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000-0003-4201-9757en_US
dc.authorid0000-0003-2811-0052en_US
dc.authorid0000-0002-4162-5563en_US
dc.contributor.authorDuman, Tuba Taslamacıoğlu
dc.contributor.authorAktaş, Gülali
dc.contributor.authorTel, Burçin Meryem Atak
dc.contributor.authorBilgin, Satılmış
dc.contributor.authorKahveci, Gizem
dc.contributor.authorKurtkulağı, Özge
dc.date.accessioned2024-03-20T11:59:42Z
dc.date.available2024-03-20T11:59:42Z
dc.date.issued2023en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim In this study, we aimed to evaluate the effectiveness of long-acting insulin analogs in the treatment of type 2 diabetes mellitus (T2DM) in our clinic. Methods Patients with T2DM who were prescribed long-acting insulin analog therapy in our internal medicine outpatient clinic between November 2017 and December 2019 were included in the study. Patients' age, gender, duration of diabetes, HbA1c values, insulin doses and injections in previous treatment, and fasting blood glucose levels before the initiation of long-acting insulin analog were recorded. Fasting blood glucose levels after the initiation of long-acting insulin analog therapy, HbA1c values, total insulin doses in the new treatment and the number of injections, and follow-up times were also recorded from the institutional database. Data of the patients during previous treatment and novel treatment were compared. Results Forty patients were included in our study. Six patients who did not attend their controls and two patients who were observed to be non-compliant even though they presented to control visit were excluded from the study. The remaining 32 patients were enrolled in the study. The average treatment follow-up period of the patients was 6 (3-8) months. Fasting blood glucose (p = 0.014) and HbA1c (p = 0.004) values were significantly reduced after long-acting insulin analog therapy compared to the values during previous treatment. Similarly, total daily insulin dose was decreased after long-acting insulin analog treatment compared to the insulin dose before long-acting insulin analog treatment (p < 0.001). The decrease in the number of daily insulin injections after long-acting insulin analogs treatment compared to the number of injections before long-acting insulin analog treatment was statistically significant (p < 0.001). Conclusion We think that the addition of new long-acting insulin analogs to the treatment in patients with T2DM may be beneficial in achieving the target blood glucose, A1c, and may also be associated with treatment compliance.en_US
dc.identifier.citationDuman, T. T., Aktas, G., Tel, B. M. A., Bilgin, S., Kahveci, G., & Kurtkulagi, O. (2023). Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus. Journal of Public Health, 31(12), 2039-2044.en_US
dc.identifier.doi10.1007/s10389-022-01769-1
dc.identifier.endpage2044en_US
dc.identifier.issn2198-1833
dc.identifier.issn1613-2238
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-85140602183en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage2039en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s10389-022-01769-1
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12099
dc.identifier.volume31en_US
dc.identifier.wosWOS:000876026400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorDuman, Tuba Taslamacıoğlu
dc.institutionauthorAktaş, Gülali
dc.institutionauthorBilgin, Satılmış
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofJournal of Public Health-Heidelbergen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.subjectLong-Acting Insulin Analogsen_US
dc.subjectHbA1cen_US
dc.subjectFasting Plasma Glucoseen_US
dc.subjectTreatmenten_US
dc.subjectBasalen_US
dc.titleEvaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
tuba-duman.pdf
Boyut:
549.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu